Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it ...
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other ...
The approval of Eli Lilly’s oral obesity drug officially ignites an intense competition with Novo Nordisk’s oral Wegovy; ...
Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual ...
"Your tenure has overseen a DESTRUCTION of shareholder value—a direct result of chronic operational shortcomings and failures ...
Looking for a biopharma job in Texas? Check out the BioSpace list of 10 companies hiring life sciences professionals like you ...
Some bosses stretch you. Others make work more bearable. Both can earn your loyalty. Only one is building your future.
As Daré Biosciences approaches a pivotal year with a key product launch ahead, the company kicked off an open public offering ...
As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is ...
If the Trump administration’s proposal passes, the FDA’s budget will be more than $200 million bigger in 2027, with plans to ...
Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie's deal with the White House to avoid tariffs. The news comes less than a week after the president ...
Gilead Sciences' latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results